After three years of medical cannabis being legal in the United Kingdom, the country has a total of only three patients with a prescription in the entire public system, noted a recent blog from RYAH Group (CSE: RYAH). The article noted that many more patients receive cannabis-derived medications, including flower and cannabis oil, through a growing number of private clinics (https://ibn.fm/mWT2d).
The blog provided an overview of the market, observing that “market analysts continue to place high hopes on the potential of the UK market. Yet, in its current form, there remains significant room for improvement to the UK system. With little to no access through the public system and the radically expensive costs associated with privately supplied medical cannabis, many patients are desperate for prescriptions,” RYAH observed. “With growing calls from patients and patient families, the UK’s medical cannabis program is at a tipping point once again.
The article pointed out that access to medical cannabis is restrictive in the country, with patients obtaining initial prescriptions through a specialist consultant rather than their general practitioners. Regulations also require patients to try at least two non-cannabis treatments before being eligible for a prescription, which can potentially mean months, if not years, of trial and error before a patient may qualify, the company reported.
However, “the most challenging condition within the UK’s medical cannabis policies is the requirement for published evidence,” the blog states. “Medical cannabis may only be prescribed if there is published scientific support for its therapeutic benefits. Most people familiar with cannabis research will appreciate the complications caused by this policy. Patient access around the world suffers because there is a lack of research.”
The country is ready for change, RYAH reports. “In 2020, Prohibition Partners suggested the UK market could reach £2.31 billion ($3.13 billion US) by 2024. Statista offered an updated estimate in 2021, predicting the market would hit $1.29 billion US by 2024. At the current pace, these numbers seem unattainable. But change is coming.
“The UK public is firmly behind medical cannabis, with more than three-quarters supportive of legal access,” the article continued. “With the growing public outcry following continued reports that the government is refusing access to this valuable therapy, change is in the air.”
The leading data technology company in plant-based medicine, RYAH is committed to providing valuable insight and transforming patient care through big data and artificial intelligence. The company is working to unearth breakthrough discoveries that will reshape the understanding of plant-based medicines.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Designations granted by leading global regulatory agencies play a critical role in advancing drug-development programs.…
Enormous resources are being channeled into studying different ways to support the immune system in its fight…
Recent research shows how chemotherapy and immunotherapy can complement each other when used together. Within…
David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers,…
Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer…
High-quality development platforms and translational research frameworks have become essential tools in rare-disease biotechnology. Soligenix…